Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

@inproceedings{Collaboration2009AspirinIT,
  title={Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials},
  author={Antithrombotic Trialists' Collaboration},
  booktitle={The Lancet},
  year={2009}
}
BACKGROUND Low-dose aspirin is of definite and substantial net benefit for many people who already have occlusive vascular disease. We have assessed the benefits and risks in primary prevention. METHODS We undertook meta-analyses of serious vascular events (myocardial infarction, stroke, or vascular death) and major bleeds in six primary prevention trials (95,000 individuals at low average risk, 660,000 person-years, 3554 serious vascular events) and 16 secondary prevention trials (17,000… CONTINUE READING
Highly Influential
This paper has highly influenced 34 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 37 times over the past 90 days. VIEW TWEETS
671 Citations
37 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 671 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Body - mass index and causespecifi c mortality in 900 000 adults : collaborative analyses of 57 prospective studies

  • E Flossmann, P Rothwell
  • Lancet
  • 2009

FAH, et al, for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with raised C-reactive protein

  • PM Ridker, E Danielson, Fonseca
  • N Engl J Med
  • 2008

Rosuvastatin to prevent vascular events in men and women with raised C - reactive protein

  • JB Buse, HN Ginsberg, GL Bakris
  • N Engl J Med
  • 2008

Similar Papers

Loading similar papers…